JPMorgan defends its Overweight rating of United Therapeutics (UTHR) despite the failure of the...

|About: United Therapeutics Corp... (UTHR)|By:, SA News Editor

JPMorgan defends its Overweight rating of United Therapeutics (UTHR) despite the failure of the phase III FREEDOM-C trial to meet its primary goal. Deutsche drops to Hold with a $70 target. Barclays defends a Buy and a $137 target. Shares -33% to $60.25.